NicOx : Garufi ... e la Rivoluzione Pharma

[doctor NO]

et si le QUORUM de l AG reporté n etait Hier à 21:34
qu une excuse parce que le partenaire n avait pas finit son emplette sur les titres de cox. il a un mois de plus mtnt. et c est bizarre cette stagnation du titre autour de 9 €. pas de hausse et de plus une baisse a 8.63 qui est vite avortée ?????



tutto è possibile<<<<

 

[doctor NO]

per il momento mi sto godendo il gain che sto realizzando vendendo nicox e comprando (oggi bell'incremeNto di titoli) OGXI.poi SI VEDRA'.NON CREDO PROPRIO CHE SU NICOX ESCA QUALCOSA ORMAI IN VISTA DELL'ASSEMBLEA NON TIRANO FUORI NIENTE.SE DOVEVANO FARE OPA GIA' L'AVREBBERO FATTO.QUINDI SARANNO 20 GIORNI INUTILI PER NICOX SEMPRE INTORNO A 9 EURO.

e bravo il nostro trader anch'io giochicchio qua e la <<vedi ho le keryx a 0,17 ed ora sono a 0,73 not so bad <<<<<<<ma le nicox le intendo come la prima casa ed il resto come alloggi per vacanze da spostatre come pedine la prima casa è dove si vive e quindi non si vende se non per comprare un castello tra qualche anno

 

[DickSIM]

raffica di pompe in arrivooooooo !

Doc spara subito un bel cesso propiziatorio!

 

[DickSIM]

qualcuno ha per caso sotto mano gli exit pol ... Come si scrive? .......... Dell'ag???
Doc sai qualcosa sulla intenzioni di voto dei tuoi adepti?

 

[doctor NO]

raffica di pompe in arrivooooooo !

Doc spara subito un bel cesso propiziatorio!

Non posso ho fatto il fioretto sai qualsiasi cosa che posto potrebbe essere fraintesa ed offendere e sfottere e di conseguenza me ne sto buonino altrimenti perdo le elezioni visto che è stato richiesto il voto tu che sei esperto perchè non fai gli exit pol

 

[doctor NO]

qualcuno ha per caso sotto mano gli exit pol ... Come si scrive? .......... Dell'ag???
Doc sai qualcosa sulla intenzioni di voto dei tuoi adepti?

sto raggruppando le pecorelle sparse ed ho una discreta adesione tra i voti mandati per corrispondenza e quelli che sto raccogliendo diciamo che un 200000 ci sono in cascina not so bad dear dick not so bad

 

[doctor NO]

Main Details

Drug NameWorld StatusPharma Status

antihypertensives, NicOxPhase I Clinical TrialActive

antihypertensives, Merck & Co

nitric oxide-donating antihypertensive (1), Merck/NicOx

NO-enalapril

Latest Change

Updated OnByLatest Change

3 Mar 2009CGPhase I trial details reported

Company Status Data

OriginatorCountryDevelopment Stage

NicOxFrancePhase I Clinical Trial

Licensee

Merck & CoUSAPhase I Clinical Trial

Activity Data

Therapy DescriptionCodeTherapy Status

Antihypertensive, otherC2B9Phase I Clinical Trial

Pharmacology DescriptionCode

Nitric oxide agonistNO+

Therapy CodePharmacology Code

C2B9NO+

Route of AdministrationRoute of Administration Code

Alimentary, poA-PO

Alimentary, generalA-UN

IndicationIndication Status

Hypertension, generalPhase I Clinical Trial

Major Events

Event DateAct/EstEventDetails

16 Jul 2007ActChange in StatusPhase I Clinical Trial

14 Nov 2006EstCompounds Identifiedantihypertensives, NicOx

22 Mar 2006ActNew Product in Pharmaprojects

Ratings

NoveltyMarket SizeSpeedTotal

Leading Compound (6)Over US$ 10000 million (5)Faster than Average (4)15

Detailed Information

NicOx and Merck & Co are developing a nitric oxide (NO)-donating derivative of an antihypertensive agent as part of their antihypertensive programme (Direct communication, NicOx, 17 Jul 2007; Company Web Page, NicOx, 15 Jan 2009). There are 3 current lead candidates (including antihypertensives, NicOx-2 (qv)), of which 1 will be selected for development (Press release, NicOx, 13 May 2009). NicOx and Merck & Co were investigating NCX-899, an NO derivative of enalapril (qv), as a prototype compound for demonstrating the increased activity of NO-donating antihypertensive agents (Press release, NicOx, 14 Nov 2006).

Marketing

NicOx has the option to co-promote (on a fee-for-detail basis) products to specialist physicians, such as cardiologists, in the US and certain major European countries. The agreement covers NO-donating derivatives of several major classes of antihypertensive agents for the treatment of high blood pressure, complications of hypertension, and other cardiovascular and related disorders. Merck has the exclusive right to develop and commercialize antihypertensives that use NicOx's NO-donating technology for the treatment of systemic hypertension. NicOx will identify lead candidates for development and Merck will fund and manage all further preclinical and clinical development activities following selection of lead compounds (Press release, NicOx & Merck, 21 Mar 2006).

Clinical

Phase I

Merck & Co is conducting a single-ascending-dose Phase Ib trial in patients with mild-to-moderate hypertension, to assess the safety, efficacy, tolerability and pharmacokinetics of the most advanced lead candidate (Press releases, NicOx, 13 May 2008 & 26 Feb 2009; Company Web Page, NicOx, 11 Feb 2009). Merck & Co have completed US Phase I dose-escalation trials in healthy volunteers with 2 lead candidates. The primary objective of the trials were to assess the safety, tolerability and pharmacokinetics of single po doses, in order to select the dose and dosing regimen for further clinical studies (Press releases, NicOx, 16 Jul 2007 & 13 May 2008). Further single- and multiple-escalating dose Phase I trials in healthy volunteers and patients with hypertension are planned with the lead candidates. Following completion of these trials, a single lead candidate will be selected for Phase II trials (Press release, NicOx, 13 May 2008).

Preclinical

In aged spontaneously hypertensive rats, NCX-899 1x/day po for 7 days resulted in significantly better reduction in systolic blood pressure cf equimolar doses of enalapril when measured on day 7, 2-6hr post dosing. The blood pressure lowering activity of NCX-899 was sustained over the full 7-day administration schedule showing that the nitric oxide-donation of NCX-899 did not induce tolerance. NCX-899 and enalapril caused a similar degree of ACE inhibition. However, NCX-899 was associated with a statistically-significant increase of basal plasma nitrate/nitrate levels compared to enalapril, suggesting that the sustained and improved activity of NCX-899 is due to nitric oxide (Press release, NicOx, 14 Nov 2006).[/size]




a che punto saremo?????????????'

 

[ficasim]

BUONGIORNO A TUTTI.....dopo aver letto purtroppo pagine e pagine di diatribe tra 2 Nicoxiani propongo un simpatico video per farci almeno 4 risate e rompere la monotonia della quotazione......

http://www.dada.it/video/1819897/Mototopo-e-Autogatto/

 

[furo]

DOC e NET ,,, con la simpatia che ho per entrambi ,,,, vi chiedo, per favore, di FINIRLA con queste discussioni e risposte inutili

diciamo che avete ragione emtrambi, però BASTA

il Forum tutto ,,,, sentitamente ringrazia

minghia, sono all'estero, in centro città su un taxi senza AC con un caldo della ,,,,, e ,,,,, devo sudare per leggere paginate di ,,,,,

concordo pienamente.
BASTA

 

[DickSIM]

the rarità effect is near to flow???